ICH E6(R3) is now effective in the EU, marking a pivotal shift in clinical trial oversight. This issue breaks down what it means and how to stay ahead.
TRI launches major overhaul of OPRA-CM
TRI’s reimagined OPRA-CM platform delivers on the true promise of RBQM, cutting through complexity to enable smarter, faster, and more focused centralized monitoring.
The Quality Issue – May 2025
In this edition, we mark National Clinical Trials Day, spotlight new Tufts CSDD research on monitoring trends, and share must-attend events.
Lessons from London
This blog explores how clinical research leaders are navigating post-Covid uncertainty, shifting buyer expectations, and the growing need for authenticity, trust, and AI-driven value.
The Quality Issue – April 2025
From Vancouver to London, this edition highlights must-attend RBQM events that offer fresh insights, regulatory updates, and real-world strategies to elevate your clinical trial oversight.
SCDM – April 2025
We’re heading to Brussels for SCDM 2025 EMEA! Visit TRI at Booth 21 to discover how our reimagined OPRA-CM platform is transforming centralized monitoring and driving RBQM success.
The Quality Issue – February 2025
In this edition, we reflect on two standout events, RBQM Summit and SCOPE 2025.
The Quality Issue – January 2025
We spotlight major developments in clinical research, from new FDA biopsy guidance and the EU’s CTIS transition deadline.
Dose Optimization in Oncology: Advancing Clinical Trial Quality
The FDA’s latest guidance on dose optimization marks a pivotal shift in oncology drug development.
TRI Joins Veeva’s Product Partner Program
TRI has joined Veeva’s Product Partner Program, integrating OPRA with Vault EDC to deliver faster, smarter RBQM.